-
Mashup Score: 80Management of infusion-related reactions in cancer therapy: strategies and challenges - 2 month(s) ago
Several anticancer therapies have the potential to cause infusion-related reactions (IRRs) in the form of adverse events that typically occur within minutes to hours after drug infusion. IRRs can range in severity from mild to severe anaphylaxis-like reactions. Careful monitoring at infusion initiation, prompt recognition, and appropriate clinical assessment of the IRR and its severity, followed by immediate management, are required to ensure patient safety and optimal outcomes. Lack of standardization in the prevention, management, and reporting of IRRs across cancer-treating institutions represents not only a quality and safety gap but also a disparity in cancer care.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 80Management of infusion-related reactions in cancer therapy: strategies and challenges - 2 month(s) ago
Several anticancer therapies have the potential to cause infusion-related reactions (IRRs) in the form of adverse events that typically occur within minutes to hours after drug infusion. IRRs can range in severity from mild to severe anaphylaxis-like reactions. Careful monitoring at infusion initiation, prompt recognition, and appropriate clinical assessment of the IRR and its severity, followed by immediate management, are required to ensure patient safety and optimal outcomes. Lack of standardization in the prevention, management, and reporting of IRRs across cancer-treating institutions represents not only a quality and safety gap but also a disparity in cancer care.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 80Management of infusion-related reactions in cancer therapy: strategies and challenges - 2 month(s) ago
Several anticancer therapies have the potential to cause infusion-related reactions (IRRs) in the form of adverse events that typically occur within minutes to hours after drug infusion. IRRs can range in severity from mild to severe anaphylaxis-like reactions. Careful monitoring at infusion initiation, prompt recognition, and appropriate clinical assessment of the IRR and its severity, followed by immediate management, are required to ensure patient safety and optimal outcomes. Lack of standardization in the prevention, management, and reporting of IRRs across cancer-treating institutions represents not only a quality and safety gap but also a disparity in cancer care.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 26Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing - 2 month(s) ago
The FUTURE trial (UMIN000029294) demonstrated the safety and efficacy of adding palbociclib after fulvestrant resistance in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) advanced and metastatic breast cancer (ABC/MBC). In this planned sub-study, cancer panel sequencing of cell-free DNA (cfDNA) was utilized to explore prognostic and predictive biomarkers for further palbociclib treatment following fulvestrant resistance.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 61Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes - 3 month(s) ago
Sexual concerns are a major unaddressed need among survivors of breast cancer (BC) with significant negative effects on quality of life. We longitudinally analyzed sexual health over time, using patient-reported outcomes.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
What is the incidence of sexual health concerns among patients diagnosed with breast cancer? In a large (n=7985) longitudinal cohort from 26 French centers, @AliceFranzoi et al report 78% incidence of any sexual concern, with <50% receiving proper support. https://t.co/bKjBGw6go6 https://t.co/qsXBnz4oEK
-
-
Mashup Score: 61Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy? - 3 month(s) ago
Controlled ovarian stimulation (COS) for oocyte/embryo cryopreservation is the method of choice for fertility preservation (FP) in young patients diagnosed with early-stage breast cancer (eBC). Nevertheless, some challenges still question its role, particularly in the neoadjuvant setting, where concerns arise about potential delay in the onset of anticancer treatment, and in hormone receptor-positive (HR+) disease, as cancer cells may proliferate under the estrogenic peak associated with stimulation.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 42Moving to ultra-short therapy to cure patients with cancer: a solution for sustainable cancer care - 3 month(s) ago
Cancer care has witnessed significant advancements over the years, leading to increased cure rates and improved overall survival. This has been mainly due to the development of innovative and more effective treatment strategies, such as immunotherapy and targeted therapies. Nonetheless, patients are increasingly exposed to potential late treatment toxicities as they live longer. Simultaneously, increasing cancer drug prices present a global challenge to treatment accessibility. As health care systems worldwide struggle with the rising number of cancer cases, there is a growing need for more sustainable and patient-centred approaches to cancer treatment.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 58Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy? - 3 month(s) ago
Controlled ovarian stimulation (COS) for oocyte/embryo cryopreservation is the method of choice for fertility preservation (FP) in young patients diagnosed with early-stage breast cancer (eBC). Nevertheless, some challenges still question its role, particularly in the neoadjuvant setting, where concerns arise about potential delay in the onset of anticancer treatment, and in hormone receptor-positive (HR+) disease, as cancer cells may proliferate under the estrogenic peak associated with stimulation.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 24Rational thresholding of circulating tumor DNA concentration for improved surveillance of metastatic breast cancer☆ - 3 month(s) ago
The use of circulating tumor DNA (ctDNA) concentration for metastatic cancer surveillance is promising, but uncertainty remains about cut-offs with clinical validity.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
What is the value of monitoring disease progression for metastatic breast cancer with ctDNA (vs Ca15.3)? In this new @ESMO_Open article, Martens et al found a complementary value for ctDNA and Ca15.3 monitoring, with high PPV to predict disease progression https://t.co/6ERPorR0MC https://t.co/aLYmxNuG4V
-
-
Mashup Score: 94Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis☆ - 3 month(s) ago
Trastuzumab deruxtecan (T-DXd) has shown promising results in patients with breast cancer brain metastases (BCBMs). We conducted a systematic review and meta-analysis to evaluate the effectiveness and safety of T-DXd in the human epidermal growth factor receptor 2 (HER2)-positive BCBM population.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet
RT @dr_yakupergun: Management of infusion-related reactions in cancer therapy: strategies and challenges https://t.co/Z24bs26uPA https://…